AI Article Synopsis
- A 52-year-old woman was diagnosed with both neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD), making this the first reported case of their coexistence.
- Tocilizumab, an antibody that targets the IL-6 receptor, was used to treat the patient and proved effective for both conditions.
- After treatment, the patient's lung issues related to iMCD improved, and she did not experience any recurrence of neurological symptoms from NMOSD.
Article Abstract
We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.4503-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!